secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001193125-25-146134
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera and Gilead sign option/license deal for CDK2 degraders; up to $750M
--------------------------------------------------------------------------

- Up to $750M total payments including $85M upfront/option exercise payments.
- Tiered royalties ranging from high-single-digit to mid-teens on net sales.
- Kymera leads all research; Gilead obtains global development/manufacturing/commercialization rights.
- CDK2 degraders target breast cancer and other solid tumors.
- Agreement announced June 25, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525146134/0001193125-25-146134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525146134/d923971d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-146134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer